LONDON (Alliance News) - Pharmaceutical company PureTech Health PLC said Thursday its independent affiliate, Alkali, has raised USD13 million in new funding.
This new funding brings Alkili's total financing for the year to USD68 million. Alkali develops video games to treat cognitive dysfunction and conditions of the brain.
Alkali's current video game treatment, AKL-T01, targets ADHD in paediatric patients and is currently under review by the US Food & Drug Administration. The financing will be used to further develop AKL-T01 as well as to created video games aimed at treating major depressive disorder and multiple sclerosis.
"This financing is an additional validation for Akili and further augments their strong cash position as they progress on their path to offer potentially safe, effective, and personalised digital treatments for patients across a range of mental health and neurological conditions," said Bharatt Chowrira, president & chief of business & strategy at PureTech.
Shares in PureTech were down 0.3% at 158.00 pence on Thursday.
PureTech (PRTC)